Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Data presented today at the 74th Scientific Sessions of the American Diabetes Association (ADA) show that treatment with Tresiba® (insulin degludec) achieves a lower rate of nocturnal hypoglycaemia compared to insulin glargine in type 2 diabetes.1 The findings are supported by real world data from the UK which demonstrate that switching from insulin glargine or insulin detemir to insulin degludec can reduce hypoglycaemia, which has cost implications for the NHS.2,3
A meta-analysis examined rates of nocturnal hypoglycaemia occurring in patients with type 2 (n=2,900) and type 1 (n=953) diabetes treated with insulin degludec and insulin glargine. The analysis reported significantly lower rates with insulin degludec in type 2 patients and numerically lower rates in type 1 patients, using a variety of definitions and timeframes for nocturnal confirmed hypoglycaemia.1
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=92728#.U6Ewk_ldWAg
Haven't heard of anyone on Tresiba here yet.
A meta-analysis examined rates of nocturnal hypoglycaemia occurring in patients with type 2 (n=2,900) and type 1 (n=953) diabetes treated with insulin degludec and insulin glargine. The analysis reported significantly lower rates with insulin degludec in type 2 patients and numerically lower rates in type 1 patients, using a variety of definitions and timeframes for nocturnal confirmed hypoglycaemia.1
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=92728#.U6Ewk_ldWAg
Haven't heard of anyone on Tresiba here yet.